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S u v v A R Y  A r u o  C o N c L U S T o N S
SUMMARY
The aim of  th is thesis was to evaluate the relat ion between impairment of  HRV
(as parameters of  autonomic dysfunct ion) in pat ients wi th CHF and the sever i ty
o f  the  d ísease,  and in  add i t ion  the  prognost ic  va lue  o f  HRV impa i rment  and
severe ventr icular arrhythmias in CHF pat ients was examined (chapter 1-3).
Further, we studied and compared the differences between the efÍects of various
drugs  on  d i f fe ren t  c l in ica l ,  neurohumora l  and HRV parameters  (chapter  4 -7) . ln
chapter 8 the current ly used drugs for CHF treatment were reviewed, wi th regard
to their  long-term effects in CHF pat ients.
In chapter 1 the resul ts of  a study including 79 pat ients wi th NYHA l- lV CHF
due to ischemic heart  d isease are presented. In th is paper the relat ions between
sever i ty of  CHF (as documented by c l in ical  and hemodynamic parameters) on the
one hand, and HRV changes on the other were analyzed, wi th a descr ipt ion of
the correlat ions between di f ferent HRV parameters and NYHA CHF class,  lef t
ventr icular eject ion f ract ion and peak VO2. ln th is study several  s igni f icant
correlat ions were found between NYHA CHF class,  lef t  ventr icular eject ion
fract ion,  peak VO2 and HRV with the interest ing f inding of  a strong relat ion
between HRV parameters and the most powerful  c l in ical  predictor of  CHF mortal-
i ty,  peak VO2. The resul ts suggest,  that  HRV may be used as (another)  c l in ical
indicator of  d isease sever i ty in CHF.
From this study the quest ion rose, whether impairment of  HRV may also
provide prognost ic informat ion in CHF, especial ly wi th respect of  mode of  death
in these pat ients.  In chapter 2 the correlat ion between cardiac mortal i ty and HRV
impairment was analyzed in a group oÍ  173 pat ients wi th lef t  ventr icular dys-
funct ion and CHF to f ind the predict ive value of  d i f ferent HRV parameters.  Of the
analyzed HRV parameters,  decreased SDNN and pNN50 were found to have an
independent predict ive value for al l -cause cardiac mortal i ty.  Whi le increased r isk
of sudden cardiac death could not be predicted by any of  the studied HRV
variables,  impairment of  pNN50 and decreased low frequency power were found
to be strongly related to increased r isk of  death due to progressive pump fai lure.
These resul ts suggest,  that  t ime domain and frequency domain HRV parameters
are essent iaÍ ly indicators of  CHF sever i ty,  and as such, may provide basic prog-
nost ic informat ion in CHt,  but  not speci f ical ly for  sudden cardiac death.
In chapter 3,  the predict ive value of  d i f ferent types of  ventr ícular arrhythmias
for cardiac mortal i ty dur ing 24 hour ambulatory ECG monitor ing was evaluated
in 211 CHF pat ients wi th stable CHF. The pr imary f inding of  th is study was, that
al though ventr icular tachycardias were predict ive for  a l l  cause cardiac death,  the
r isk of  sudden cardiac death was signi f icant ly increased in pat ients having faster
and longer ventr icular tachycardias,  which may be representat ive of  an enhanced
adrenergic dr ive in these pat ients.  In th is paper the suggest ion is made, that  as
sympathet ic act ivat ion may be an under ly ing factor of  l i fe- threatening arrhyth-
mias and increased mortal i ty in CHF, est imat ion and reduct ion of  cardiac sympa-
thet ic act ivat ion may be important in the r isk assessment and treatment of  CHt,
respectively.
As physic ians increasingly real ized the causal  re lat ion between neurohumoral
act ivat ion and disease progression, new drugs with neurohumoral  inhibi tory
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propert ies achieved growing at tent ion in the t reatment of  CHF. In part  l l l ,  the
long-term effects of  d i f ferent neurohumoral  modulat ing drugs in CHF were
evaluated.
ln chapter 4 an observat ional  mortal i ty analysis is presented, which was con-
ducted in B5 pat ients wi th sustained ventr icular tachycardias or ventr icular
f ibr i l lat ion,  and depressed lef t  ventr icular funct ion.  ln th is study, drug treatment
was guided by resul ts of  programmed electr ical  st imulat ion.  The resul ts showed
the independent benef ic ia l  value of  long-term B-blocker therapy on prognosis in
pat ients wi th ventr icular dysfunct ion and severe arrhythmias.  However,  whether
the reduct ion in mortal i ty caused by B-blockers was due to a reduct ion of  the
arrhythmogenic ef fects of  e levated levels of  serum catecholamines, or pr imari ly
to ant i - ischemic ef fects,  is  not c lear,  and further studies are needed on this issue.
In chapter 5-8,  the autonomic and neurohumoral  modulat ing ef fects of
di f ferent CHF drugs were studied, wi th special  interest  in therapy induced
modif icat ions of  HRV. As indicated in the Introduct ion,  in the last  years,  analysis
o f  HRV has  been used in  the  non- invas ive  va lua t ion  o f  d rug  induced au tonomic
changes, and as such as a surrogate end-point  for  drug ef f icacy in CHF. However,
s ince HRV changes are related to changes in hemodynamics,  the object  of  these
studies was to focus on comparison between HRV, neurohumoral  and hemo-
dynamic modulat ing ef fects of  var ious CHF drugs.
ln chapter 5,  the c l in ical  and autonomic ef fects of  long-term metoprolol
t rea tment  in  24  pa t ien ts  w i th  c l in ica l l y  s tab le ,  mi ld  CHF were  eva lua ted .  In  th is
study a discrepancy between the cl in ical  and autonomic ef fects of  long-term P-
blocking therapy was observed. Whi le af ter  6 months t reatment there were no
effects of  metoprolol  on exercise parameters,  an improvement of  some of  the
studied autonomic parameters (HRV var iables and autonomic funct ion tests)  was
seen, al though most of  these ef fects did not reach stat ist ical  s igni f icance. The
observed trend of  improvement of  autonomic tests and HRV was suggest ive of  a
correct ion of  the sympathet ic / parasympathet ic imbalance and an improvement
o f  the  depressed vaga l  tone,  w i thout  any  change in  serum norep inephr ine .
ln chapter 6 the resul ts of  a study evaluat ing hemodynamic and autonomic
effects of  a relat ively new phosphodiesterase inhibi tor  -sater inone- dur ing short-
term infusion are presented. In th is study, which included 36 pat ients wi th NYHA
l l l - lv  CHF, sater inone was found to have convincing vasodi lat ing propert ies
dur ing 3 hours infusion, which was ( in part)  at  the expense of  an increase in
heart  rate.  lnterest ingly,  these hemodynamic changes were not accompanied by
increase in serum norepinephr ine or impairment of  HRV parameters.
In chapter 7 the c l in ical  and autonomic ef fects of  long-term ibopamine
treatment were evaluated. ln th is study, which was conducted in 59 opt imal ly
treated, pr imari ly NYHA l l l  CHF pat ients (added to ACE-inhibi tor ,  d iuret ics and
digoxin),  ibopamine was not found to have a s igni f icant ef fect  on exercise
parameters or serum levels of  neurohormones, al though HRV analysis suggested
an improvement  o f  the  au tonomic  func t ion .  Pr imar i l y  HRV var iab les ,  tha t  re f lec t
vagal  tone, improved, suggest ive of  a benef ic ia l  ef fect  of  ibopamine on the
parasym pathet ic dysf  u nct ion.
In chapter 8 a review on the inf luence of  var ious drugs on CHF mortal i ty is
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mortal i ty of  the last  decades. As pointed out in th is chapter,  the current ly estab-
l i shed,  op t ima l  therapy  o f  CHF inc ludes  ACE- inh ib i to rs ,  d iu re t i cs ,  and d igox ín .
Recent studies wíth B-blockers and ( to a lesser degree) wi th some calc ium channel
blockers suggest,  that  these drugs may also gain a role in the t reatment of
pat ients wi th lef t  ventr icular dysfunct ion and CHF. ln th is respect i t  is  important
to note,  that  drugs which are proven to have benef ic ia l  ong-term effects in CHF
pat ients,  were also found to have ei ther a benef ic ia l  or  neutral  ef fect  on neuro-
humoral  parameters.  On the other hand, a favorable ef fect  on neurohormones /
HRV does not necessar i ly  lead to a long-term benefíc ia l  ef fect ,  suggest ing that
other factors st i l l  p lay an important role ( lntroduct ion,  Table l l l ) .
C O N C L U S I O N S
ln the observat ional  studies presented in th is thesís,  which were conducted in
pat ients wi th c l in ical ly stable CHF, a s igni f icant correlat ion between impairment
of  HRV and disease sever i ty was found. Furthermore, impaired HRV was demon-
strated to have prognost ic value for al l  cause mortal i ty in CHF pat ients,  a l though
t ime domain and frequency domain parameters of  HRV were not found to have
any role in the predict ion of  sudden cardiac death,
ln the drug intervent ion studies of  the thesis,  the induced hemodynamic,
neurohumoral  and HRV modif icat ions were compared, wi th focus on the value
and interpretat ion of  drug induced HRV changes. In 2 studies wi th metoprolol
and ibopamine, t rends toward improvement of  HRV were observed dur ing drug
treatment,  in the absence of  benef ic ia l  hemodynamic or neurohumoral  ef fects.  ln
the case of  sater inone, HRV remained unchanged, whi le hemodynamics improved
and posi t ive chronotropic ef fects of  the drug were observed dur ing sater inone
infusion. The observed lack of  correlat ion between HRV modif icat ions,  and
hemodynamic and neurohumoral  drug ef fects in these studies suggest,  that
al though HRV may be used to measure autonomic dysfunct ion in CHE, i ts value in
the evaluat ion of  drug induced autonomic changes is l imi ted, at  least  in these
groups of  opt imal ly t reated CHF pat ients.  Consequent ly,  drug induced HRV
changes need to be interpreted with caut ion,  and physic ians hould take several
other c l in ical  and neurohumoral  factors also into account,  when evaluat ing drug
effects in CHF. One important aspect in th is regard is,  that  some drugs are
apparent ly able to improve HRV, whi le at  the same t ime they exert  posi t ive
chronotropic ef fects.  Combinat ion of  these ef fects is paradoxical ,  and the in-
crease of  heart  rate is obviously not benef ic ia l  in CHF. ïherefore,  drug induced
changes of  heart  rate should be also integrated in the standard analysis of  HRV.
The studies presented in th is thesis show, that  neurohormones and HRV are
good measures of  CHF sever i ty and mortal i ty.  Howevel  wi th regard to evaluat ion
of drug ef fects,  the value of  autonomic parameters is less c lear in pat ients wi th
opt imal ly t reated, stable CHF. The value of  these parameters may be l imi ted by
several  drug induced factors,  that  are not ref lected by plasma neurohormones or
HRV changes. Plasma neurohormones and HRV analysis alone therefore do not
appear to be rel iable,  as surrogate end-points in the long-term drug evaluat ion
of opt imal ly t reated CHF pat ients.
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